Notable Labs, Ltd. NTBL
0.25 USD 0.00 (+0.00%)
At closeOct 22, 2024, 4:00 PM EDT
0.2396 Day range 0.3055
0.10 52-week range 4.24
- YTD
- 0.00%
- 1 year
- 0.00%
News
benzinga.com Why iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket 
benzinga.com Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 47%; Here Are 20 Stocks Moving Premarket 
globenewswire.com Notable Labs to Present Data on September 4th at SOHO 2024 Society of Hematologic Oncology (SOHO) session to highlight volasertib program Phase 2 volasertib AML program expected to begin in the coming months FOSTER CITY, Calif., Aug. 29, 2024 (GLOBE…
globenewswire.com Notable Labs Announces CEO Transition Thomas Bock, MD resigns as CEO; Joseph Wagner, PhD, CSO, appointed interim CEO Company affirms plan to initiate volasertib Phase 2 program in the coming months FOSTER CITY, Calif., Aug. 26, 2024…
zacks.com Bears are Losing Control Over Notable Labs (NTBL), Here's Why It's a 'Buy' Now Notable Labs (NTBL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean…
globenewswire.com Notable Labs to Participate in Fireside Chat at the Citizens JMP Securities Life Sciences Conference 2024 FOSTER CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs” or the “Company”), a clinical-stage precision oncology company developing new cancer…
zacks.com Notable Labs (NTBL) Upgraded to Buy: What Does It Mean for the Stock? Notable Labs (NTBL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
globenewswire.com Notable Labs Reports 2023 Financial Results and Provides a Business Update FOSTER CITY, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing new cancer therapies…
globenewswire.com Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024 FOSTER CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing a new class of cancer…
globenewswire.com Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform FOSTER CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing a new class of cancer…
globenewswire.com Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform FOSTER CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs”), a clinical-stage therapeutics platform company developing a new class of cancer…
globenewswire.com Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform FOSTER CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs”), a clinical-stage therapeutics platform company developing a new class of cancer…
globenewswire.com Notable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment FOSTER CITY, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs”), a clinical-stage therapeutics platform company developing a new class of cancer…
globenewswire.com Notable Reports Predictive Precision Medicine Platform (PPMP) Accurately Predicted Fosciclopirox Trial Outcome - PPMP Accurately Predicted Patient Outcomes in Fosciclopirox Phase 2a Leukemia Trial - - Predictive Results Further Advance PPMP and Corroborate Outcomes from 4 PPMP Validation Trials - - Furthers…
prnewswire.com Notable Labs Donates $60,000 to MDS Foundation to Accelerate Progress for Patients with Myelodysplastic Syndromes Funds will help advance MDS Education, Advocacy and Research SAN DIEGO , Dec. 13, 2023 /PRNewswire/ -- Notable Labs, Ltd. ("Notable") (Nasdaq: NTBL), a clinical stage therapeutic platform company…
prnewswire.com Notable Labs Funds Myelodysplastic Syndromes Foundation with $60,000 Grant Funds will help advance MDS Education, Advocacy and Research SAN DIEGO , Dec. 11, 2023 /PRNewswire/ -- Notable Labs, ("Notable") (Nasdaq: NTBL), a clinical stage therapeutic platform company…
globenewswire.com Notable Labs to Participate in JMP Securities Hematology and Oncology Summit FOSTER CITY, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (“Notable”) (Nasdaq: NTBL), a clinical stage therapeutic platform company developing predictive precision medicines for…
globenewswire.com Notable Labs Announces Filing of Form 10-Q for Third Quarter 2023 -Summarizes third quarter 2023 financials of pre-Merger VBLT as of September 30th- -Third quarter financial information of Notable Labs, Inc. and pro forma combined financial information of Notable…
benzinga.com Why Nuvve Holding Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Gainers Shift Technologies, Inc. (NASDAQ: SFT) shares climbed 107.8% to $0.2239. Shift Technologies recently said it will file for Chapter 11 bankruptcy protection.
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023 
benzinga.com Why Talaris Therapeutics Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket Gainers Biocept, Inc. (NASDAQ: BIOC) shares surged 91.8% to $0.98 in pre-market trading after falling over 6% on Tuesday. Biocept recently filed for Chapter 7 bankruptcy in the U.S. Bankruptcy Court…